TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Effectiveness of UACE followed by suction curettage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response (complete and partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged stable disease rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post surgical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical complications after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with termination of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Influence of genomic regions on drug and gene interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of esophagojejunal anastomotic leak
Endpoint domain: Adverse events/effects
Primary endpoint: Musculoskeletal ultrasonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Washed-out Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of patients with IBS according to Rome IV Diagnostic Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Behavioral and Psychological Symptoms of Dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Two-Point Discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: California Verbal Learning Test-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TFR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum estrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement of ADAS-cog/12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and Tolerability Assessed by Development of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with IBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve at steady-state for a dosing interval (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum plasma concentration at steady-state within a dosing interval (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration at steady-state (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute intracranial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Goodglass-Kaplan communication scale (GKS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aphasia Check-list (ACL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of Doxil versus Doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melphalan exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Logarithmic Change in Colony Counts of Facial Propionibacterium Acnes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Serum Concentration of C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Margin width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Best Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change of NF-kB Protein Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of people needed for tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relative Change in Whole Liver Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline of 10-item voice handicap index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in scores of The Canadian Occupational Performance Measure (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pediatric Balance Scale (PBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Functional Independence Measure for Children (WeeFIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Accuracy of AI in identifying anatomical landmarks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Androgens and IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction of delayed graft function (DGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Immune cell polarization (Th1/Th2; M1/M2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dialysis time (months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pharmacodynamic biomarker analysis in tumour tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self processing and self focus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence of Anti-HGT-1110 Antibodies in Cerebrospinal Fluid (CSF) and Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prolonged reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lower Extremity Deep Vein Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pulmonary Embolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) of AL2846
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of dose-limiting toxicity(ies) (DLT[s]) of AL2846
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with hyperglycemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Corrected count increment (CCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sexual dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of patellar crepitus complication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Spontaneous Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious complications following liver resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva-plasma ratio or saliva-serum ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophilic count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Received Zostavax Immunization or Had Natural Exposure to VZV
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fat taste preference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change brain response to milkshake anticipation and consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neuronal encoding of prediction error processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cyst resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Freedom
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: plasma pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Fluorescein Staining Type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Fluorescein Staining Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of TKI258
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Pain and Disability Index (Pain Level)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Range of motion (Shoulder Impairment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inappropriate pre-operative testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of RT-PCR response or Southern blot response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of residual disease in patients who have achieved a complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morcellation or resection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ease of use of the new pharyngeal airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to relieve upper airway obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hands off approach during deep sedation/MAC anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants with Injection Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Non-recurrence at Week 52
Endpoint domain: Mortality/survival
Primary endpoint: Change in percent predicted forced expiratory volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of DLT (dose limiting toxicity)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in shoulder function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Lenalidomide with Epoetin beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of using 18F-DCFPyL to detect cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes in fetal middle cerebral artery Doppler indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma treprostinil concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjustment errors of the subjective visual/haptic/postural vertical
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraabdominal pressure (IAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of erection maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Female partner's sexual quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Immune-related Overall Response Rate (irORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood levels of telaprevir and raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Values of C. albicans and E. faecalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 17 hydroxyprogesterone responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in serum ADMA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Difference in serum SDMA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tear evaporation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-related Adverse Events ≥ Grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Treatment Emergency Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergency Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Surgical Interruptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Percent Reduction from Baseline in Non-Nodular Inflamed Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Percent Reduction from Baseline in Non-Inflamed Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in LEFS scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Walking and Remembering Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Enhanced positive neurocognitive effects on the CPT-IP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Enhanced positive neurocognitive effects on the Spatial working memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Enhanced positive neurocognitive effects on the PRLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adherence rate to mercaptopurine (MEMS®)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence rate to mercaptopurine (red cell TGN levels)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average daily Modified Lung injury score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of opioid overdose deaths
Endpoint domain: Mortality/survival
Primary endpoint: Socket Comfort Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence rates of brain metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prescription Opioid Misuse Index - POMI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CIED infection
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic BP control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lot-to-lot consistency of HRV vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inferiority of liquid formulation versus lyophilised formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of subjects presenting complications
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency rate of early post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve From 0 to Infinity (AUC0-∞) for EVG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ for COBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ for FTC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ for Tenofovir (TFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Accurately Select a Safe Child Restraint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Install the Child Restraint Accurately Into the Vehicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Properly Position the Child Restraint in the Vehicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful ERCP procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Satisfaction with NCI CRC RAT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived risk of developing CRC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intent to be screened within six months
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Myocardial substrate metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Hepatic Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Responders at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Gastrointestinal Symptoms Rating Scale (GSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Drug Tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial glycaemia (iAUC 0-30 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: St. George's Respiratory Questionnaire (SGRQ) Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acute Short Form 12 version 2 (Acute SF-12v2) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global Efficacy questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment free survival
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose of RNR inhibitor COH29
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Success Rate based on change in Investigator's Global Assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in inflammatory lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the curve (AUC) for plasma procyanidin-derived metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic value of microRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: synchronous cerebral hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: electric patterns recorded with EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Next day performance in a standardized test of car driving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth Whitening Shade Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Care Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dependence in Activities of Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction With Health and Social Care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative intensive care output criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Total PVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concerns about dying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distressing emotions related to HIV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug Levels in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Haematology, Biochemistry and Virology Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Magnetic resonance imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of disease in Primary Hyperoxaluria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake rate of cervical screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Lucentis Injections received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Brain activation in Stop Signal Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trier Social Stress Test- Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Child Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mechanical ventilator free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes